One of Life Science Leader’s newest editorial advisory board (EAB) members is Pamela Reilly Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics....
Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services....
BioEclipse Therapeutics™ today announced that it has established operations at a new corporate headquarters and laboratory facilities at the Open Medicine Institute (OMI) Collaboratory, a 104,000 square-foot facility in Mountain View, CA. ...
In 2006, Contag cofounded ConcentRx (pronounced concen-tricks), but the biopharma rebranded in 2016 to become BioEclipse Therapeutics. When asked about the details of what transpired between those 10 years, Contag was extremely transparent, sharing not only her frustrations but the wisdom she earned throughout this unusual business journey....
BioEclipse Therapeutics™ announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for the Company’s lead drug candidate, CRX100....
BioEclipse Therapeutics™ today announced that it has raised $7.7 million in its Series A-1 financing round, which was led by Revelis Capital Group, LLC and managed by VENTURE.co Brokerage Services, LLC, with participation from Tsingyuan Ventures, DEFTA Partners, TSVC (TEEC Angel Fund) and Plum Alley. BioEclipse has now raised a...
BioEclipse Therapeutics™ today announced that Goldman Sachs has recognized BioEclipse Co-Founder & CEO, Pamela R. Contag, Ph.D., as one of the 100 Most Intriguing Entrepreneurs of 2018 at the seventh annual Goldman Sachs Builders + Innovators Summit in Santa Barbara, California....
For the last 20 years, Pamela Contag has studied cancer. And in that time, the world’s understanding of cancer has changed dramatically. “I remember when people were saying ‘One gene, one protein,” which we now know is wrong,” she told Drug Delivery Business News....
